Edwards Lifesciences Corporation will discuss the company's focused strategy for long-term sustainable growth, provide an update on its technology pipeline to serve more patients and share financial ...
The global structural heart devices market is witnessing remarkable growth, driven by factors such as the rising prevalence of structural heart diseases, expanding indications for transcatheter ...
Edwards Lifesciences EW has announced one-year, real-world data on its SAPIEN 3 Ultra RESILIA valve at the PCR London Valves 2024. These data add to the extensive body of evidence on the company’s ...
Elsewhere in the world of aortic and cardiovascular devices, AccurKardia has received breakthrough designation from the US Food and Drug Administration (FDA) for its Aortic Valve Stenosis (AVS) ...